Fundraising Fox
San Francisco · Seed–Late Stage · 41 people tracked
Also known as 5AM · 5AM VENTURE MANAGEMENT, LLC
Find your way into 5AM Ventures
Sign up to see every warm intro you have to 5AM Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 5AM Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
5AM Ventures invests across the life sciences, primarily backing private therapeutic companies with an emphasis on early-stage, Series A opportunities through its Ventures Strategy. Its Opportunities Strategy targets small and mid-cap public and later-stage private biotech and life science companies. Through the 4:59 initiative, the firm takes a hands-on approach to discovering, incubating, and funding breakthrough science, partnering with academics and entrepreneurs — often acting as an extension of the operating team — to generate proof-of-concept data enabling a Series A financing. The firm concentrates on biopharmaceuticals, drug delivery technologies, and life science instruments aimed at solving important healthcare needs.
Source: firm website, verified Sep 29, 2026.
Team · 41 people
from the firm's website & public directories
Founder mafia
4 people who came through 5AM Ventures went on to found or lead other companies.
What they invest in
from 71 of 133 portfolio companiesBiotech ×62Healthtech ×35Medical Devices ×16Deep Tech ×8AI & Machine Learning ×7Digital Health ×6SaaS ×3Enterprise Software ×2
HQs:United States×68United Kingdom×2
Who they back
founder profiles across 27 portfolio companiesFounding team size:solo founder×132 founders×73 founders×54+ founders×2
Where their founders studiedfrom 16 founders with education data
Stanford University ×2
What their founders studiedfrom 15 founders with field-of-study data
Life Sciences ×6Medicine ×5Chemistry ×4Business & Management ×2Economics ×2Physics ×2
Where their founders worked beforefrom 19 founders with career history
Eli Lilly ×2Harvard Medical School ×2Vectura Group plc. ×2
Investments · 133 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 62024 · 22023 · 32022 · 22021 · 122020 · 42019 · 42018 · 62017 · 32016 · 72015 · 870 dated
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatKush M Parmar· per SEC Form D
Co-investorsAgent CapitalMPM BioImpactMRL Ventures FundRoche Venture FundTCG CrossoverWellington Management
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)
Board seatBrian Daniels· per SEC Form D
Co-investorsBain Capital Life SciencesDeerfield Management Company
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatAndrew J. SchwabAndy Schwab· per SEC Form D
Co-investorsAndreessen HorowitzLongwood FundPolaris Partners
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Board seatJohn D. DiekmanBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersGV (Google Ventures)Nextech InvestBiotechnology Value FundWuXi Healthcare Ventures
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Board seatScott M. Rocklage· per SEC Form D
Co-investorsALTITUDE LIFE SCIENCE VENTURESARCH Venture PartnersPolaris Partners
Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.
BiotechHealthtechNew Haven, US
Stephen Uden(Founder)inMartin W. Mackay(Chairman of the Board of Directors)inJon(Chief Financial Officer)
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentPivotal Life SciencesSolasta Ventures+2 more
Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
BiotechBedford, US
Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)inHuw Nash(Executive Officer)inIan F. Smith(Chief Executive Officer and Director)Jason Hoitt(Chief Patient Officer)inThomas E. Leggett(Chief Financial Officer)
Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018
Co-investorsScion Life SciencesRTW Investments L.P.
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+2 more
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)
Co-investorsForesite CapitalOrbiMedRA CapitalVivo Capital
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+7 more
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investorsOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City CapitalJanus Henderson Investors+2 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures+2 more
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders.
HealthtechFarmington, US
Jeffrey M. Fryer(Executive Officer, Director)Martin W. Mackay(Executive Officer, Director)Stephen Uden(Executive Officer, Director)
Co-investorsCanaan PartnersPivotal Life Sciences
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investorsOUP (Osage University Partners)RA CapitalPureTech Health
BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)
Co-investorsPfizer VenturesPfizer Venture Investments
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investorsAtlas VentureRA CapitalEQT Life SciencesGimvSixty Degree CapitalVivo Capital+3 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersAtlas VentureSanofi Ventures
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina VenturesOUP (Osage University Partners)AlexandriaLilly Asia VenturesS28 Capital
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)David Allison(Director)inKeno Gutierrez(Director)in
Co-investorsNovartis Venture FundRoche Venture FundVersant VenturesBioGeneration VenturesWestlake Village BioPartners
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Board seatKush M ParmarArthur Tzianabos· per SEC Form D
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesRA CapitalSofinnova VenturesCowen Healthcare Investments+2 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatBrian Daniels· per SEC Form D
Co-investorsEcoR1 CapitalRA CapitalvenBio PartnersWellington ManagementvenBio Global Strategic
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Board seatScott M. Rocklage· per SEC Form D
Co-investorsAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inStephen Knight(Director)in
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsAju IB InvestmentCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta VenturesViking Global+10 more
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)in
Board seatDeborah Palestrant· per SEC Form D
Co-investorsAccess BiotechnologyAscenta CapitalForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Pioneering the development of prescription digital therapeutics.
HealthtechBoston, US
Corey McCann(Executive Officer, Director)inAntoun Nabhan(Executive Officer)Christopher Guiffre(Executive Officer)
BoardAndrew Schwab(Director)inTimothy Petersen(Director)inZack Lynch(Director)in
Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016
Co-investorsJAZZ Venture PartnersArboretum VenturesGeneral CatalystOCA VenturesSeyen CapitalSoftBank Group+2 more
.png)
Develops tools to formulate and manufacture nanoparticles used as medicines; acquired by Danaher in 2021.
BiotechVancouver
Andrew Booth(Director)R. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Euan Ramsay(Executive Officer)Daniel Nixon(Director)
Board seatAndrew J. Schwab· per SEC Form D · $13.4M raise · filed Nov 2016
Co-investorsBDC Industrial Innovation Venture FundInnovative Solutions CanadaPage One VenturesRising TideTelegraph Hill Partners
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)inJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatAndrew Schwab· per SEC Form D
Co-investorsArboretum VenturesF-Prime CapitalTelegraph Hill PartnersHealthQuest CapitalSofinnova Ventures
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)inEmily Conley(Executive Officer, Director)in
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Board seatDeborah Palestrant· per SEC Form D
Co-investorsOrbiMedAtlas VentureQiming Venture PartnersQiming Venture Partners USA
BiotechResearch Triangle Park, US
Andrew Jordan(Executive Officer, Director)John Taylor(Executive Officer, Director, Promoter)Robert Tarran(Director)
BoardDonald Rose(Director)
Board seatBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersHatteras Venture Partners
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsAvoro Capital AdvisorsFrazier Life SciencesSamsara BioCapitalVenrock Healthcare Capital PartnersVivo Capital
Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve.
BiotechHealthtechMountain View, US
Edwin S Kamemoto(Executive Officer)inMark K Oki(Executive Officer)inThomas B King(Executive Officer, Director)inMichael J Simms(Executive Officer)James V Cassella(Executive Officer)Robert A Lippe(Executive Officer)in
Co-investorsNew Enterprise Associates (NEA)
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investorsHealthCapRobin Hood VenturesRosetta Capital Ltd.Versant VenturesSoleus Capital
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyRA CapitalvenBio PartnersDeerfield Management CompanyOrbiMedVenrock
Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.
AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US
Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)Karin L.(Founder)in
Co-investorsEndurance28Harmonix FundPerot JainStartXTaihill Venture
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
AI & Machine LearningBiotech
Leonard Zon(Founder)Richard Young(Founder)
BoardChristopher Walsh, MD, PhD(Scientific Advisor)
Co-investorsAndreessen HorowitzFlucas VenturesNorthpond Ventures
HealthtechHayward, US
GUY DIPIERRO(Director)inALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsCota CapitalEmergent Medical Partners, LLPFountain Healthcare PartnersKaiser Permanente VenturesMission Bay CapitalCanaan Partners+2 more
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)inCarol Gallagher(Director)in
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech InvestOUP (Osage University Partners)Clarus VenturesOrbiMed+1 more
Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection.
BiotechHealthtechWaltham, US
Jonathan Violin(Executive Officer, Director)inKenneth Evan Thompson(Executive Officer)
BoardLeon Moulder(Director)
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)
BoardAndrew Schwab(Director)in
Co-investorsAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+2 more
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly CapitalAgent CapitalCatalio Capital Management+8 more
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investorsCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners8VCAtlas VenturePanacea VentureTaiho Ventures, LLCTakeda Ventures
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investorsARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity InvestmentsHBM Healthcare Investments+5 more
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Co-investorsB Capital GroupvenBio Global StrategicvenBio PartnersWestlake Village BioPartners
.jpeg){kind=logo}
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Brian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)Michael Gallatin, PhD(Co-Founder, SAB Chair)Chuhan Chung(Chief Medical Officer)in
Co-investorsFrazier Life SciencesFrazier Healthcare PartnersWu Capital
The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.
Gaming
Co-investorsSanofi Ventures
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)inMickey Kertesz(Founder)Stephen Quake(Founder)Tim Blauwkamp(Founder)
Co-investorsDCVC (Data Collective)HBM Healthcare InvestmentsHBM PartnersKhosla VenturesLightspeed Venture PartnersSeventure Partners+3 more
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)Thomas J. Cahill(Director)
Co-investorsCathay HealthNewpath PartnersPolaris Partners
Platform addressing PR industry complexity and scaling publisher relationships.
Co-investorsOIF VenturesOur Innovation FundVolition CapitalHive Ventures
Magnetic Particle Imaging (MPI) is an imaging technology that detects iron oxide nanoparticle tracers using time-varying magnetic fields to create medical images with high contrast and sensitivity.
Deep TechHealthtechMedical Devices
Co-investorsAlumni VenturesCloudStone CapitalEvolution VC PartnersInnolinks VenturesSand Hill AngelsShangBay Capital LLC+2 more
RarePath is a biotech platform that creates pathways for scientists to develop cures for rare and ultra-rare diseases by partnering with academic researchers, biotech firms, and patient foundations to fund, license, and commercialize therapies.
BiotechSan Francisco, US
Lalarukh Haris Shaikh(Founder)in
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+11 more
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)inKLAUS VEITINGER(Director)in
Co-investorsOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
Immunotherapy company developing NOUS-209 for the prevention of Lynch syndrome-associated cancers.
Co-investorsAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM VenturesRevelation Partners+6 more
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesColorcon VenturesAlexandriaDCVC (Data Collective)DCVC Bio+1 more
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US
Brett Ewald(Chief Operating Officer, Founding Member)inAlyssa Levin(Chief Financial Officer)inPaul Grayson(Chief Executive Officer)in
Co-investorsFrazier Life SciencesDCVC Bio
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life SciencesDCVC BioFrazier Healthcare PartnersWestlake Village BioPartners
Redx is a clinical-stage biotechnology company developing small molecule targeted medicines focused on fibrotic diseases, leveraging ROCK pathway inhibitors and novel targets.
BiotechHealthtechMedical Devices
Lisa Anson(Chief Executive Officer)
BoardBernard Coulie(Independent Director)
Co-investorsAbingworthREDMILEPerscitus LLPSofinnova Partners
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investorsEpidarex CapitalF-Prime CapitalSanofi VenturesSofinnova Partners
Scientist.com operates an online marketplace and platform for life science research, helping scientists find providers, scope projects, compare proposals, manage compliance, and track spend.
AI & Machine LearningB2B MarketplacesBiotechSaaS
Kevin Lustig(Founder)inDan Kaganin
Co-investorsBootstrap Venture PartnersTRANSFORMATION CAPITAL
scPharmaceuticals was a commercial-stage biopharmaceutical company that developed FUROSCIX, an FDA-approved subcutaneous formulation of the diuretic furosemide for treating fluid overload in heart failure and kidney disease patients.
BiotechLexington, US
Pieter Muntendam(Executive Officer, Director)
BoardMette Kirstine Agger(Director)Kush Parmar(Director)inDorothy Coleman(Director)Leonard Schaeffer(Director)
Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.
CybersecurityEnterprise SoftwareSaaSCharleston, US
Glenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)
Co-investorsCheckmate Capital Group LLCRoche Venture Fund
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)inCraig Parker(Executive Officer, Director)Tim Kutzkey(Director)in
Co-investorsAccess BiotechnologyThe Column GroupHorizons Ventures
TMRW Life Sciences builds an FDA-cleared automated platform for managing and storing frozen eggs and embryos, using RFID tracking and an "ivfOS" digital database to monitor and secure specimens.
Digital HealthFemTechHealthtechMedical DevicesNew York, US
Joshua Abram(Director)inTara Comonte(Director)inAlan Murray(Director)in
BoardAndrew Schwab(Director)Vinay Shah(Director)Emily Drabant Conley(Director)in
Co-investorsGV (Google Ventures)TRANSFORMATION CAPITALWhat If Ventures
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investorsARCH Venture PartnersClarus VenturesK2 HealthVentures
Viveve publishes evidence-based health guides covering six core topics—heart health, women's health, nutrition, hormones, sexual health, and aging—written without pseudoscience or supplement marketing.
Digital HealthHealthtechMedia & EntertainmentWellness & Fitness
Co-investorsAvoro Capital Advisors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Agilis BiotherapeuticsBird Rock BioGenePeeksIgenica BiotherapeuticsKinestral TechnologiesPulmatrix OperatingPurigen Biosystems, Inc.RennoviaAchaogenAlexzaAmbrxAmbrx BiopharmaArvinasAtterocorAudentesBellerophonCalibriumCellular ResearchCeterixChronoCidaraCinCorCinCor PharmaCleave TherapeuticsDeverraDVSEntradaEnvoyEpirusExpansion TherapeuticsFaradayFellow HealthFlexionHALIO, INC.IgenicaIkariaIlypsaInclineLatigoLifordiMarcadiaMiikanaMillendoNido BioNido BiosciencesNodTheraNohla TherapeuticsNoviraNovira TherapeuticsPanomicsPearPearlPhaseRxPhenomixPNIPortalProlynxPurigenRally BiotherapeuticsRelypsaReprotechSemprusSemprus BioSciencesSkyeSkye BioscienceSynosiaWildcat
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 36
15 IPOs · 21 acquisitions · showing 35Entrada Therapeutics, Inc.NASDAQ: TRDACabaletta BioNASDAQ: CABACamp4 Therapeutics CorpNASDAQ: CAMPIdeaya BiosciencesNASDAQ: IDYAPulmatrixNASDAQ: PULMRallybio, LLCNASDAQ: RLYBStoke TherapeuticsNASDAQ: STOKArvinas Holding Co. LLCNASDAQ: ARVNCrinetics PharmaceuticalsNASDAQ: CRNXDisc MedicineNASDAQ: IRONEnliven TherapeuticsNASDAQ: ELVNQ32 BioNASDAQ: QTTBRallybio HoldingsNASDAQ: RLYBVor BiopharmaNASDAQ: VORBird Rock Bioacq. by Skye BioscienceAmbrxacq. by Johnson & JohnsonAudentesacq. by Astellas PharmaCalibriumacq. by Novo NordiskCellular Researchacq. by Becton, Dickinson and Company (BD)Ceterixacq. by Smith+NephewFlexionacq. by Pacira BioSciences, Inc.Igenicaacq. by Pierre FabreIkariaacq. by Mallinckrodt PharmaceuticalsMarcadiaacq. by RocheMiikanaacq. by EntreMed, Inc. (now CASI Pharmaceuticals)Noviraacq. by Johnson & Johnson (Janssen Pharmaceutical Companies)Novira Therapeuticsacq. by Johnson & Johnson (Janssen)Panomicsacq. by AffymetrixPhaseRxacq. by Roivant SciencesPurigenacq. by Bionano GenomicsRelypsaacq. by Galenica (Vifor Pharma)Scientistacq. by GHO Capital PartnersscPharmaceuticalsacq. by MannKind CorporationSemprusacq. by TeleflexSynosiaacq. by Biotie Therapies
Portfolio news
latest coverage across their companies
Aprea · biospace.com · Sep 10, 2026
Q32 Bio · stocktitan.net · Jul 15, 2026
Pulmatrix · prnewswire.com · May 15, 2026
Kinaset Therapeutics · finsmes.com · Jan 12, 2026
Lifordi Immunotherapeutics · finsmes.com · Nov 19, 2025
Adverum Biotechnologies · biospace.com · Oct 27, 2025
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Vor Biopharma | 17.2% | $18.00 | Feb 2021 | $110.5M |
| Q32 Bio | 18.6% | $16.00 | Mar 2018 | $107.6M |
| Entrada Therapeutics, Inc. | 13.9% | $20.00 | Nov 2021 | $83.2M |
| Rallybio, LLC | 11.5% | $13.00 | Jul 2021 | $46.5M |
| Rallybio Holdings | 11.5% | $13.00 | Jul 2021 | $46.5M |
| Cabaletta Bio | 13.7% | $11.00 | Oct 2019 | $35.4M |
| Ideaya Biosciences | 13.9% | $10.00 | May 2019 | $27.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has 5AM Ventures made?
- 5AM Ventures has 133 tracked investments, 36 of which have exited, including 8 dated in the last 24 months.
- What stage does 5AM Ventures invest at?
- 5AM Ventures invests at the Seed, Series A, Growth, Late Stage stages.
- What is 5AM Ventures's typical check size?
- 5AM Ventures typically writes checks of $100K – $4M.
- What sectors does 5AM Ventures focus on?
- 5AM Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices, New Materials.
- Where is 5AM Ventures located?
- 5AM Ventures is headquartered in San Francisco, US.
- Does 5AM Ventures lead rounds?
- Yes, 5AM Ventures leads investment rounds.
- Who does 5AM Ventures co-invest with?
- 5AM Ventures most often shares deals with RA Capital, Frazier Life Sciences, Sanofi Ventures, among 94 tracked co-investors.
Co-investors · 40
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Westlake Village BioPartners is a Los Angeles-based life science venture capital firm that builds and incubates biotech companies around top entrepreneurs, providing hands-on support from ideation through clinical and commercial stages.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
▶28 more co-investors
Polaris PartnersVersant VenturesvenBio PartnersThe Column GroupAbingworthForesite CapitalDeerfield Management CompanyNextech InvestAndreessen HorowitzEQT Life SciencesArboretum VenturesFrazier Healthcare PartnersConnecticut InnovationsAlta PartnersLongwood FundJMI EquityTelegraph Hill PartnersKleiner PerkinsVenrockSR One Capital ManagementAndera PartnersHatteras Venture PartnersNew Leaf Venture PartnersHealthQuest CapitalIllumina VenturesHive VenturesForbionAltitude Ventures Management, Llc
Firms observed investing alongside 5AM Ventures, from public investor directories. Shared companies are the overlap with 5AM Ventures's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.